Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
44.75
Dollar change
-0.16
Percentage change
-0.36
%
Index- P/E- EPS (ttm)-2.99 Insider Own25.36% Shs Outstand57.83M Perf Week-1.32%
Market Cap2.59B Forward P/E- EPS next Y-3.49 Insider Trans-0.16% Shs Float43.20M Perf Month-8.56%
Income-154.94M PEG- EPS next Q-0.78 Inst Own70.96% Short Float9.49% Perf Quarter56.14%
Sales43.95M P/S58.93 EPS this Y-9.06% Inst Trans-1.85% Short Ratio7.08 Perf Half Y96.53%
Book/sh6.16 P/B7.26 EPS next Y-6.64% ROA-36.96% Short Interest4.10M Perf Year150.14%
Cash/sh6.14 P/C7.29 EPS next 5Y- ROE-51.36% 52W Range17.15 - 52.03 Perf YTD62.73%
Dividend Est.- P/FCF- EPS past 5Y-18.50% ROI-42.24% 52W High-14.00% Beta1.10
Dividend TTM- Quick Ratio5.34 Sales past 5Y7.00% Gross Margin- 52W Low160.93% ATR (14)1.90
Dividend Ex-Date- Current Ratio5.34 EPS Y/Y TTM-4.12% Oper. Margin-356.22% RSI (14)49.36 Volatility3.47% 4.43%
Employees- Debt/Eq0.03 Sales Y/Y TTM5.68% Profit Margin-352.56% Recom1.00 Target Price60.30
Option/ShortYes / Yes LT Debt/Eq0.03 EPS Q/Q41.23% Payout- Rel Volume0.40 Prev Close44.91
Sales Surprise-6.93% EPS Surprise-34.43% Sales Q/Q-16.19% EarningsFeb 28 AMC Avg Volume578.40K Price44.75
SMA20-4.38% SMA506.21% SMA20055.10% Trades Volume234,581 Change-0.36%
Date Action Analyst Rating Change Price Target Change
TodayInitiated Truist Buy $69
Mar-04-24Reiterated Needham Buy $42 → $65
Nov-02-23Initiated Canaccord Genuity Buy $45
Aug-21-23Initiated TD Cowen Outperform
Aug-02-22Initiated Stifel Buy $38
Feb-11-22Initiated BMO Capital Markets Outperform $45
Feb-10-22Initiated Needham Buy $45
Nov-17-21Resumed Guggenheim Buy $44
Jun-07-21Upgrade Citigroup Neutral → Buy $24 → $31
Apr-08-21Initiated William Blair Outperform
Mar-06-24 10:11AM
08:00AM
06:15AM
Mar-05-24 04:30PM
Mar-04-24 08:00AM
04:15PM Loading…
Feb-28-24 04:15PM
Feb-20-24 10:00AM
Feb-16-24 03:57AM
Jan-31-24 08:00AM
Jan-09-24 05:07AM
Dec-28-23 09:55AM
Dec-12-23 09:55AM
Dec-05-23 12:00PM
Dec-04-23 12:15PM
Dec-02-23 08:40PM
11:05AM Loading…
Nov-26-23 11:05AM
Nov-23-23 09:55AM
Nov-07-23 09:55AM
Nov-02-23 04:12PM
Nov-01-23 08:00AM
Oct-31-23 10:01AM
Oct-26-23 10:02AM
Oct-23-23 07:30AM
Oct-17-23 05:00AM
Oct-15-23 07:58PM
Oct-13-23 09:00AM
Oct-06-23 09:32AM
Sep-11-23 03:45AM
Sep-07-23 07:36PM
Aug-31-23 08:00AM
09:44AM Loading…
Aug-21-23 09:44AM
Aug-09-23 09:53PM
04:01PM
Aug-07-23 07:15PM
04:26PM
Jul-28-23 08:00AM
Jul-05-23 04:01PM
Jun-29-23 04:30PM
Jun-28-23 07:35AM
Jun-15-23 07:47AM
May-31-23 08:00AM
May-21-23 03:28PM
May-11-23 12:00PM
May-10-23 09:55AM
May-05-23 10:24AM
May-04-23 08:15PM
04:25PM
May-02-23 10:01AM
May-01-23 10:00AM
Apr-17-23 10:15AM
Apr-14-23 11:10AM
11:10AM
Apr-10-23 10:16AM
Mar-14-23 04:30PM
04:30PM
09:08AM
Feb-28-23 04:25PM
Feb-23-23 11:37AM
Feb-20-23 10:00AM
Feb-15-23 06:22AM
Feb-10-23 03:44AM
Feb-01-23 08:00AM
Jan-28-23 01:30PM
Jan-19-23 11:06AM
05:37AM
Jan-09-23 06:05AM
Jan-08-23 09:00AM
Nov-09-22 08:00AM
07:09AM
Nov-03-22 09:05AM
07:51AM
Oct-26-22 04:00AM
Oct-12-22 02:19PM
07:00AM
Sep-07-22 04:10PM
Sep-01-22 08:00AM
Aug-08-22 06:45PM
04:17PM
Jul-14-22 02:31PM
Jun-28-22 08:42AM
Jun-06-22 02:54PM
Jun-05-22 11:00AM
Jun-03-22 09:55AM
08:00AM
May-26-22 05:00PM
09:35AM
May-25-22 09:35AM
May-17-22 08:00AM
May-14-22 08:00AM
May-09-22 06:35PM
04:29PM
Apr-27-22 04:01PM
Apr-25-22 08:00AM
Apr-08-22 01:00PM
Apr-06-22 08:00AM
Mar-18-22 09:10AM
Mar-08-22 04:35PM
Feb-28-22 04:37PM
Feb-03-22 08:00AM
Jan-26-22 07:07AM
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shuman HarryVP Controller, PAODec 19 '23Sale26.681153,0687,002Dec 20 04:05 PM
Silverman Peter B.COO & GCDec 15 '23Sale25.0022,386559,6500Dec 18 05:15 PM
Shuman HarryVP Controller, PAODec 08 '23Sale24.442506,1107,117Dec 12 04:04 PM
Shuman HarryVP Controller, PAODec 01 '23Option Exercise0.002,50007,942Dec 04 04:05 PM
Shuman HarryVP Controller, PAODec 01 '23Sale24.5857514,1337,367Dec 04 04:05 PM
Shuman HarryVP Controller, PAOJun 01 '23Option Exercise0.002,50006,017Jun 01 04:21 PM
Shuman HarryVP Controller, PAOJun 01 '23Sale21.4857512,3515,442Jun 01 04:21 PM
Iwicki Mark TDirectorApr 14 '23Option Exercise7.2773,576534,67973,576Apr 17 08:26 AM
Liu HuiEVP, CBO & Head of Merus USApr 06 '23Option Exercise7.8698,085770,948156,016Apr 10 12:43 PM